Want to join the conversation?
Specialty pharmaceutical company $AGN posted 4Q15 net loss of $700.5MM or $2.13 loss per share vs. $732.9MM or $2.75 loss per share in 4Q14. Non-GAAP diluted EPS from continuing operations was $3.41. Net revenues from continuing operations rose 74% to $4.2Bil, helped by increased revenue in US, Medical Aesthetics, International and Anda brands.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)